Diferencia entre revisiones de «Cefdinir»
(Restore original dosing content alongside dynamic SMW tables)
 
(No se muestran 6 ediciones intermedias de 4 usuarios)
Línea 1: Línea 1:
==General==
==General==
*Type: Third generation [[cephalosporin]]
*Type: [[Is Generation::3rd generation]] [[Is DrugClass::cephalosporin]]
*Dosage Forms: capsule, oral suspension
*Dosage Forms: capsule, oral suspension
*Dosage Strengths: capsule: 300mg; oral suspension: 125mg/5mL, 250mg/5mL
*Dosage Strengths: capsule: 300mg; oral suspension: 125mg/5mL, 250mg/5mL
Línea 8: Línea 8:
==Adult Dosing==
==Adult Dosing==
*600mg/d divided q12-24hrs for 10 days for [[CAP]], chronic [[bronchitis]], acute [[sinusitis]], [[strep pharyngitis]], [[cellulitis]]
*600mg/d divided q12-24hrs for 10 days for [[CAP]], chronic [[bronchitis]], acute [[sinusitis]], [[strep pharyngitis]], [[cellulitis]]
===Indications by Disease===
{{#ask: [[Has DrugName::Cefdinir]] [[Has Population::Adult]]
|?Treats disease=Disease
|?Has Dose=Dose
|?Has Context=Context
|format=table
|limit=50
|mainlabel=-
|headers=show
|sort=Treats disease
}}


==Pediatric Dosing==
==Pediatric Dosing==
*14mg/kg/d PO divided q12-24hrs x10 days, max of 600mg/day
*14mg/kg/d PO divided q12-24hrs x10 days, max of 600mg/day
===Indications by Disease===
{{#ask: [[Has DrugName::Cefdinir]] [[Has Population::Pediatric]]
|?Treats disease=Disease
|?Has Dose=Dose
|?Has Context=Context
|format=table
|limit=50
|mainlabel=-
|headers=show
|sort=Treats disease
}}


==Special Populations==
==Special Populations==
Línea 28: Línea 54:
===Common===
===Common===
*Diarrhea
*Diarrhea
*[http://genericpharmaceuticals.science/cefdinir-colored-stool/ Stool discoloration] which is guiac negative and returns to normal color after cessation
*Bloody stools which are guiac negative and returns to normal color after cessation<ref>Graves R, Weaver SP. Cefdinir-associated "bloody stools" in an infant. J Am Board Fam Med. 2008;21(3):246-248. doi:10.3122/jabfm.2008.03.070242</ref>


==Pharmacology==
==Pharmacology==
Línea 164: Línea 190:
<references/>
<references/>


[[Category:Pharmacology]]
[[Category:Pharmacology]] [[Category:ID]]

Revisión actual - 02:38 20 mar 2026

General

  • Type: 3rd generation cephalosporin
  • Dosage Forms: capsule, oral suspension
  • Dosage Strengths: capsule: 300mg; oral suspension: 125mg/5mL, 250mg/5mL
  • Routes of Administration: PO
  • Common Trade Names: Omnicef

Adult Dosing


Indications by Disease

DiseaseDoseContext
Periorbital cellulitis300 mg BIDOutpatient
Pyelonephritis300mg BID PO x 10-14 daysOutpatient

Pediatric Dosing

  • 14mg/kg/d PO divided q12-24hrs x10 days, max of 600mg/day


Indications by Disease

DiseaseDoseContext
Acute otitis media14mg/kg/day BID x7-10 daysPrior Month Treatment
Periorbital cellulitis14 mg/kg per day, divided every 12 hours, max daily 600 mgOutpatient
Pyelonephritis14mg/kg/day PO divided BID x 10 days (max 600mg/day)Pediatric Outpatient

Special Populations

  • Pregnancy Rating: B
  • Lactation: Probably safe
  • Renal Dosing
    • Adult: CrCl <30, 300mg q24hrs; CrCl <10, 300mg q48hrs; supplement after HD
    • Pediatric: CrCl <30, 7mg/kg q24, max 300mg/dose; supplement after HD
  • Hepatic dosing not defined

Contraindications

  • Allergy to class/drug

Adverse Reactions

Serious

Common

  • Diarrhea
  • Bloody stools which are guiac negative and returns to normal color after cessation[1]

Pharmacology

  • Half-life: 100 min
  • Metabolism: Not appreciably metabolized
  • Excretion: Urine (7-25% as unchanged drug)
  • Mechanism of Action: Bactericidal, inhibits bacterial cell wall synthesis

Antibiotic Sensitivities[2]

Group Organism Sensitivity
Gram Positive Strep. Group A, B, C, G S
Strep. Pneumoniae S
Viridans strep S
Strep. anginosus gp X1
Enterococcus faecalis R
Enterococcus faecium X1
MSSA S
MRSA R
CA-MRSA R
Staph. Epidermidis I
C. jeikeium X1
L. monocytogenes R
Gram Negatives N. gonorrhoeae S
N. meningitidis X1
Moraxella catarrhalis S
H. influenzae S
E. coli S
Klebsiella sp S
E. coli/Klebsiella ESBL+ R
E coli/Klebsiella KPC+ R
Enterobacter sp, AmpC neg R
Enterobacter sp, AmpC pos R
Serratia sp R
Serratia marcescens X1
Salmonella sp S
Shigella sp S
Proteus mirabilis S
Proteus vulgaris I
Providencia sp. X1
Morganella sp. R
Citrobacter freundii R
Citrobacter diversus X1
Citrobacter sp. S
Aeromonas sp X1
Acinetobacter sp. X1
Pseudomonas aeruginosa R
Burkholderia cepacia X1
Stenotrophomonas maltophilia X1
Yersinia enterocolitica X1
Francisella tularensis X1
Brucella sp. X1
Legionella sp. R
Pasteurella multocida S
Haemophilus ducreyi X1
Vibrio vulnificus X1
Misc Chlamydophila sp X1
Mycoplasm pneumoniae X1
Rickettsia sp X1
Mycobacterium avium X1
Anaerobes Actinomyces X1
Bacteroides fragilis X1
Prevotella melaninogenica X1
Clostridium difficile X1
Clostridium (not difficile) X1
Fusobacterium necrophorum X1
Peptostreptococcus sp. X1

Key

  • S susceptible/sensitive (usually)
  • I intermediate (variably susceptible/resistant)
  • R resistant (or not effective clinically)
  • S+ synergistic with cell wall antibiotics
  • U sensitive for UTI only (non systemic infection)
  • X1 no data
  • X2 active in vitro, but not used clinically
  • X3 active in vitro, but not clinically effective for Group A strep pharyngitis or infections due to E. faecalis
  • X4 active in vitro, but not clinically effective for strep pneumonia

See Also

References

  1. ↑ Graves R, Weaver SP. Cefdinir-associated "bloody stools" in an infant. J Am Board Fam Med. 2008;21(3):246-248. doi:10.3122/jabfm.2008.03.070242
  2. ↑ Sanford Guide to Antimicrobial Therapy 2014
Obtenido de «https://www.wikem.org/w/index.php?title=Cefdinir&oldid=386570»